Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Live-Attenuated Herpes Zoster Vaccine Booster Following Recombinant Vaccine
NCT07753265Phase 1Not yet recruiting
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Aug 2026
- Primary completion
- Sep 2026
01
Overview
Phase 1, open-label, single-arm trial of zoster vaccine live in herpes zoster (HZ), sponsored by Changchun BCHT Biotechnology Co. Primary endpoint: Immunogenicity at 30 days. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
zoster vaccine live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT07753265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07753265.